Role of aspirin and statin therapy in patients with cerebral cavernous malformations
•Patients with cerebral cavernous malformations (CCM) can present with acute hemorrhages with or without symptoms.•Surgery has been the mainstay of treatment and currently, it is the most commonly used alternative to long-term follow-up.•The protective effect between aspirin or statins and hemorrhag...
Gespeichert in:
Veröffentlicht in: | Journal of clinical neuroscience 2020-08, Vol.78, p.246-251 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Patients with cerebral cavernous malformations (CCM) can present with acute hemorrhages with or without symptoms.•Surgery has been the mainstay of treatment and currently, it is the most commonly used alternative to long-term follow-up.•The protective effect between aspirin or statins and hemorrhages in CCMs has been subject to animal studies.•In this study, patients using aspirin and statins had less hemorrhages compared to patients under no treatment.
Stagnant blood flow and organizing thrombus are intralesional components of patients with cerebral cavernous malformations (CCM). Stasis and inflammation are mechanisms of growth, lesional instability and acute hemorrhages with or w/o symptoms. We evaluate the association of pre-diagnostic aspirin and/or statin use with acute hemorrhages at diagnosis. Patients with a CCM diagnosis were identified and categorized according to their medications on admission into four groups (no therapy, statin, aspirin, combined). The primary outcome was an acute hemorrhage (with or w/o symptoms) at diagnosis reported in a standardized manner from the T2 weighted magnetic resonance image. A multivariate generalized linear mixed models (GLMM) was utilized to conduct per-lesion analysis. We identified 446 patients with 635 lesions. An acute hemorrhage at diagnosis was observed in 31% of the patients. There were 328 patients without statin or aspirin therapy, 34% of whom presented with acute hemorrhage. Of patients on aspirin therapy at diagnosis, 25% presented with hemorrhage. Of patients on statin therapy, 26% had a hemorrhage at diagnosis. Combined therapy in 44 patients demonstrated a lower proportion of patients with acute hemorrhages (7 patients, 16% incidence). A GLMM showed that patients in the combined therapy group to have significantly lower odds of having an acute hemorrhage at diagnosis compared to the reference group of no therapy (OR 0.24; 95% CI 0.09–0.59; P = 0.002). Patients with a CCM receiving therapy with both aspirin and statins were less likely to present at diagnosis with acute hemorrhage. |
---|---|
ISSN: | 0967-5868 1532-2653 |
DOI: | 10.1016/j.jocn.2020.04.012 |